Secure Ileal Pouch-Anal Anastomosis for Histologic Indeterminate Colitis

Area of Science:

• Gastroenterology and Surgical Innovation
• Inflammatory Bowel Disease (IBD) Diagnostics
• Molecular Biomarker Discovery

Background:

• Indeterminate colitis (IC) presents diagnostic challenges, complicating treatment decisions for inflammatory bowel disease (IBD).
• Accurate differentiation between ulcerative colitis (UC) and Crohn's colitis (CC) is crucial for effective surgical management, particularly restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA).
• Misdiagnosis of IC can lead to suboptimal treatment, increased morbidity, and unnecessary healthcare costs.

Purpose of the Study:

• To identify a reliable biomarker for distinguishing UC from CC in patients with IC.
• To improve the accuracy of diagnosing colonic IBD subtypes.
• To guide patient selection for curative pouch surgery (RPC-IPAA).

Main Methods:

• Investigated the expression of human alpha defensin 5 (HD5) in colonic mucosal lining.
• Identified 'colonic ileal metaplasia' as a potential biomarker in Crohn's colitis (CC).
• Evaluated the diagnostic performance of these markers in IC cohorts.

Main Results:

• HD5 expression was found to be restricted in colon crypt mucosal lining areas.
• Colonic ileal metaplasia showed potential as a biomarker for differentiating CC and UC.
• The proposed biomarker achieved a positive predictive value (PPV) of 96% for distinguishing CC and UC among IC patients.

Conclusions:

• The identified biomarker (HD5 and colonic ileal metaplasia) can significantly circumvent the imprecise diagnosis of IC.
• This diagnostic advancement offers tangible benefits over current diagnostic pathways for IBD.
• Further development and regulatory navigation are necessary for widespread clinical adoption of this molecular diagnostic technology.